American Academy of Asthma, Allergy and Immunology (AAAAI)

BioCryst will attend the 2026 American Academy of Asthma, Allergy and Immunology (AAAAI) from Feb 27 – Mar 2, 2026.

  • Long-Term, Sustained, Robust Hereditary Angioedema Attack Suppression with Navenibart Administered Every 3 and 6 Months: ALPHA-SOLAR Interim Results
    AAAAI | 2026 | HAE
  • Navenibart Demonstrates Durable Efficacy and Tolerability Across Biological Sexes: Subgroup Analysis from the ALPHA-STAR Trial
    AAAAI | 2026 | HAE
  • Navenibart Delays Time to First Attack in Hereditary Angioedema: Results from ALPHA-STAR 
    AAAAI | 2026 | HAE
  • Real-World Attack Rate Reductions After Berotralstat Initiation Among Patients with Hereditary Angioedema with Normal C1-Inhibitor Stratified by Prior Long-Term Prophylaxis
    AAAAI | 2026 | HAE
  • Impact of Berotralstat on Hereditary Angioedema Attack Rates in Patients with C1-Inhibitor Deficiency: Real-World Evidence Stratified by Prior Long-Term Prophylaxis
    AAAAI | 2026 | HAE

Have questions about any of our medicines that are approved or in development, or would you like to be connected with an MSL?

Have questions about our company?